{"product_id":"astellas-five-forces-analysis","title":"Astellas Pharma Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAstellas Pharma faces intense competitive rivalry driven by blockbuster patents expiring and aggressive global peers, while buyer power and regulatory hurdles shape pricing and product launch dynamics; supplier influence is moderate but critical for biologics, and threat of new entrants is low due to high R\u0026amp;D barriers though substitutes and biosimilars pose growing risk. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Astellas Pharma’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized CDMO and Biologic Manufacturing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAstellas increasingly outsources complex biologics and gene therapies to specialized CDMOs; as of late 2025 only about 10–15 global facilities can reliably support large‑scale viral vector production, giving suppliers strong bargaining power. This concentration lets CDMOs push up pricing—industry rates rose ~18% YoY in 2024–25 for viral vector fill\/finish—risking margin compression for Astellas. Capacity shortfalls also threaten launch timing for late‑stage assets, potentially deferring revenue and inflating development costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Academic Research Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAstellas frequently licenses early-stage innovations from universities and small biotechs, and these IP holders wield high bargaining power because their patents and platforms are critical to Astellas’ oncology and immunology pipeline; in 2024 Astellas disclosed over 30 active external collaborations, many tied to late-preclinical assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Scientific and Technical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe 2025 shortage of specialized researchers—regenerative medicine and data science—raises supplier power: Astellas competes with Pfizer, Roche, and venture-backed biotech for scarce talent, pushing salaries up ~15–25% and equity demands; losing a lead scientist can delay a phase II\/III program by 12–24 months, risking millions in sunk R\u0026amp;D (typical late-stage program costs $50–200M annually) and derailing strategic timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiche Chemical and Biological Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAstellas depends on a few certified global suppliers for high‑purity chemical precursors and biological reagents; single‑source risks can halt manufacturing for top sellers like Xtandi (USD 4.5B 2024 sales) and Izervay (launched 2023).\u003c\/p\u003e\n\u003cp\u003eSuppliers exploit scarcity to secure premium pricing and multi‑year contracts, raising COGS volatility and requiring strategic inventory or dual‑sourcing investments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle‑source risk: few certified vendors\u003c\/li\u003e\n\u003cli\u003eHigh impact: Xtandi ~4.5B 2024 sales\u003c\/li\u003e\n\u003cli\u003eSupplier leverage: premium pricing, long contracts\u003c\/li\u003e\n\u003cli\u003eMitigation: inventory, dual sourcing, qualification costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Digital and AI Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Astellas folds AI into drug discovery and trial ops, reliance on major cloud providers and niche AI startups rises, concentrating supplier power—AWS, Microsoft Azure, and Google Cloud held roughly 60% of global cloud market in 2024, tightening options.\u003c\/p\u003e\n\u003cp\u003eHigh switching costs for petabyte-scale datasets and proprietary algorithms give these suppliers pricing leverage; migrating exabytes can cost millions and delay programs months.\u003c\/p\u003e\n\u003cp\u003eBecause AI stacks sit in core R\u0026amp;D, digital vendors act as strategic partners with influence over timelines, licensing costs, and roadmaps, affecting Astellas’ cost base and speed to clinic.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCloud market share: AWS\/Azure\/GCP ≈60% (2024)\u003c\/li\u003e\n\u003cli\u003eData migration: petabyte transfers cost $100k–$2M+ and take weeks–months\u003c\/li\u003e\n\u003cli\u003eProprietary models: vendor lock-in raises licensing fees 10–30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Power Squeezes Astellas: CDMO, Talent, Reagents \u0026amp; Cloud Drive COGS Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power for Astellas due to concentrated CDMO capacity (10–15 global viral vector sites, viral fill\/finish costs +18% YoY 2024–25), scarce specialized talent (+15–25% salary inflation 2025), single‑source chemical\/reagent risks (Xtandi $4.5B 2024 sales), and cloud vendor dominance (AWS\/Azure\/GCP ~60% 2024) driving COGS and timeline risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eStat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eViral CDMO sites\u003c\/td\u003e\n\u003ctd\u003e10–15 global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViral fill\/finish cost change\u003c\/td\u003e\n\u003ctd\u003e+18% YoY (24–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTalent salary rise\u003c\/td\u003e\n\u003ctd\u003e+15–25% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtandi sales\u003c\/td\u003e\n\u003ctd\u003e$4.5B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud share\u003c\/td\u003e\n\u003ctd\u003e~60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Astellas Pharma, this Porter’s Five Forces overview uncovers competitive drivers, buyer\/supplier power, entry barriers, substitutes and disruptive threats shaping the company’s pricing, profitability and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Astellas—highlighting patent-driven supplier power, regulatory barriers deterring entrants, moderate buyer leverage, rivalry from big pharmas, and substitution risks from biosimilars for fast strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental Health Authorities and Single-Payer Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Japan and several EU countries, government health authorities are Astellas Pharma's main buyers, giving them strong bargaining power via national price controls and routine price cuts that can slash revenue per unit by 10–30% after reviews.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 tighter public budgets forced tougher negotiations and cost-effectiveness thresholds—HTA bodies now reject or demand bigger discounts for ~20–35% of new submissions, pressuring launch economics and margin forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Benefit Managers and Private Insurers in the US\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn the US, large Pharmacy Benefit Managers (PBMs) and private insurers consolidate purchasing for ~300–350 million covered lives, extracting rebates often 20–50% off list prices; Astellas must win preferred formulary placement to keep drugs affordable and accessible. Failure to secure status risks rapid share loss as patients are steered to lower-cost generics or competitor brands; Astellas saw formulary exclusions cut launch uptake by \u0026gt;30% in comparable cases. Negotiations therefore directly affect net revenue and volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Procurement Groups and Large Healthcare Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cplarge hospital systems and group purchasing organizations buy specialty oncology urology drugs in bulk giving them leverage to push astellas for price discounts service terms the u.s. top gpos account of as consolidation continued through m up year-over-year buyers increased bargaining power pressuring margins on high-cost therapies. gpo contracts often tie rebates volume formulary placement forcing trade-offs between list net revenue. what this estimate hides: clinical value patent protection can still limit buyer leverage.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Patient Advocacy Groups and Public Opinion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups have pushed for lower drug prices and faster access; in 2024 about 62% of US adults supported Medicare drug price negotiation, amplifying pressure on firms like Astellas Pharma (2024 revenue ¥1.12 trillion) to justify pricing.\u003c\/p\u003e\n\u003cp\u003eThey influence regulators and policymakers, leading to calls for transparent pricing and reimbursement reforms that can compress margins and force Astellas to adapt long-term pricing strategies.\u003c\/p\u003e\n\u003cp\u003eThe groups’ political mobilization increases the risk of price-control legislation, which could reduce net pricing power and alter product launch economics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% US public support for Medicare negotiation (2024)\u003c\/li\u003e\n\u003cli\u003eAstellas FY2024 revenue ¥1.12 trillion\u003c\/li\u003e\n\u003cli\u003eHigher transparency demands → pricing pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformed and Value-Conscious Individual Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern patients research treatments and compare cost-benefit, with 72% of US adults using the internet for health info (Pew Research 2021), pressuring Astellas to prove value per patient.\u003c\/p\u003e\n\u003cp\u003eIn areas with multiple options, preference for fewer side effects or easier delivery raises demand for patient support programs, adding to SG\u0026amp;A costs; Astellas spent ¥249.2 billion on SG\u0026amp;A in FY2024.\u003c\/p\u003e\n\u003cp\u003eThis consumer shift forces Astellas to show clear outcomes and value—else risk losing share to competitors with stronger patient engagement and adherence tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e72% use online health info (Pew 2021)\u003c\/li\u003e\n\u003cli\u003eFY2024 SG\u0026amp;A: ¥249.2B (Astellas)\u003c\/li\u003e\n\u003cli\u003ePatient preference drives program spend, affects adherence and market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers squeeze Astellas: governments, PBMs and GPOs slash prices, rebates crush revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers—governments, PBMs\/insurers, GPOs and informed patients—hold strong leverage over Astellas through price controls, rebates and formulary placement; public buyers drive 10–30% routine cuts, PBM rebates commonly 20–50%, and top 10 GPOs cover ~80% US hospital purchasing (2024–25), directly cutting net revenue and launch uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eKey Metric\u003c\/th\u003e\n\u003cth\u003eImpact on Astellas\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment (JP\/EU)\u003c\/td\u003e\n\u003ctd\u003e10–30% routine price cuts\u003c\/td\u003e\n\u003ctd\u003eLower unit revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\/Insurers (US)\u003c\/td\u003e\n\u003ctd\u003eRebates 20–50%\u003c\/td\u003e\n\u003ctd\u003eNet price compression\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\/Hospitals\u003c\/td\u003e\n\u003ctd\u003eTop 10 = ~80% purchasing\u003c\/td\u003e\n\u003ctd\u003eVolume-based discounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\/Advocacy\u003c\/td\u003e\n\u003ctd\u003e62% support Medicare negotiation (2024)\u003c\/td\u003e\n\u003ctd\u003ePolicy pressure on pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAstellas Pharma Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Astellas Pharma Porter's Five Forces analysis you'll receive immediately after purchase—no surprises, fully formatted and ready for use.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the actual deliverable: a complete, professionally written assessment of competitive rivalry, buyer and supplier power, threat of substitutes, and barriers to entry.\u003c\/p\u003e\n\u003cp\u003eOnce you buy, you’ll get instant access to this same file—downloadable and ready for strategic or investment use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747391222137,"sku":"astellas-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/astellas-five-forces-analysis.png?v=1772197994","url":"https:\/\/growthsharematrix.com\/products\/astellas-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}